However, a three-arm trial in recurrent NPC [56] showed a positive signal: the combination of rAd-p53 with chemoradiotherapy achieved a higher tumor response rate and longer PFS compared to chemoradiotherapy alone (the rAd-p53 + CRT arm had the best outcomes, although exact figures were not reported). Here, TP53 is linked to neoplasm.